Literature DB >> 15202519

Molecular pathogenesis of non-Hodgkin's lymphoma: the role of Bcl-6.

Laura Pasqualucci1, Oxana Bereshchenko, Oxana Bereschenko, Huifeng Niu, Ulf Klein, Katia Basso, Roberta Guglielmino, Giorgio Cattoretti, Riccardo Dalla-Favera.   

Abstract

Non-Hodgkin's lymphomas (NHL) form a heterogeneous group of diseases, with diffuse large B-cell lymphoma (DLBCL) comprising the largest subgroup. The commonest chromosomal translocations found in DLBCL are those affecting band 3q27. In 35% of DLBCL cases, as well as in a small fraction of follicular lymphomas, the normal transcriptional regulation of Bcl-6 is disrupted by these chromosomal translocations. In addition, about three-quarters of cases of DLBCL display multiple somatic mutations in the 5' non-coding region of Bcl-6, which occur independently of chromosomal translocations and appear to be due to the IgV-associated somatic hypermutation process. Bcl-6 is a 95-kD nuclear phosphoprotein belonging to the BTB/POZ (bric-a-brac, tramtrack, broad complex/Pox virus zinc finger) zinc finger family of transcription factors. It has been suggested that Bcl-6 is important in the repression of genes involved in the control of lymphocyte activation, differentiation, and apoptosis within the germinal center, and that its down-regulation is necessary for normal B-cells to exit the germinal center. Bcl-6 remains constitutively expressed in a substantial proportion of B-cell lymphomas. Recently, acetylation has been identified as a mode for down-regulating Bcl-6 activity by inhibition of the ability of Bcl-6 to recruit complexes containing histone deacetylases (HDAC). The pharmacologic inhibition of two recently identified deacetylation pathways, HDAC- and silent information regulator (SIR)-2-dependent deacetylation, results in the accumulation of inactive acetylated Bcl-6 and thus in cell cycle arrest and apoptosis in B-cell lymphoma cells. These results reveal a new method of regulating Bcl-6, with the potential for therapeutic exploitation. These studies also indicate a novel mechanism by which acetylation promotes transcription, not only by modifying histones and activating transcriptional activators, but also by inhibiting transcriptional repressors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15202519     DOI: 10.1080/10428190310001621588

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  32 in total

Review 1.  Epigenetic therapy of lymphoma using histone deacetylase inhibitors.

Authors:  Maribel Cotto; Fernando Cabanillas; Maribel Tirado; María V García; Eileen Pacheco
Journal:  Clin Transl Oncol       Date:  2010-06       Impact factor: 3.405

2.  Antilymphoma therapy with a Bcl-6 inhibitor.

Authors:  Peter McLaughlin
Journal:  Curr Hematol Malig Rep       Date:  2009-10       Impact factor: 3.952

3.  BCL6 canalizes Notch-dependent transcription, excluding Mastermind-like1 from selected target genes during left-right patterning.

Authors:  Daisuke Sakano; Akiko Kato; Nisarg Parikh; Kelly McKnight; Doris Terry; Branko Stefanovic; Yoichi Kato
Journal:  Dev Cell       Date:  2010-03-16       Impact factor: 12.270

4.  EBNA2 interferes with the germinal center phenotype by downregulating BCL6 and TCL1 in non-Hodgkin's lymphoma cells.

Authors:  Francesco Boccellato; Eleni Anastasiadou; Paola Rosato; Bettina Kempkes; Luigi Frati; Alberto Faggioni; Pankaj Trivedi
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

5.  Association of Ig/BCL6 translocations with germinal center B lymphocytes in human lymphoid tissues: implications for malignant transformation.

Authors:  Xuwei Yang; Koutetsu Lee; Jonathan Said; Xun Gong; Ke Zhang
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

6.  Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas.

Authors:  B Belinda Ding; J Jessica Yu; Raymond Y-L Yu; Lourdes M Mendez; Rita Shaknovich; Yonghui Zhang; Giorgio Cattoretti; B Hilda Ye
Journal:  Blood       Date:  2007-10-19       Impact factor: 22.113

7.  Bone marrow aspirate and biopsy: a pathologist's perspective. II. interpretation of the bone marrow aspirate and biopsy.

Authors:  Roger S Riley; David Williams; Micaela Ross; Shawn Zhao; Alden Chesney; Bradly D Clark; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

Review 8.  The biology of human lymphoid malignancies revealed by gene expression profiling.

Authors:  Louis M Staudt; Sandeep Dave
Journal:  Adv Immunol       Date:  2005       Impact factor: 3.543

9.  Sequential transcription factor targeting for diffuse large B-cell lymphomas.

Authors:  Leandro C Cerchietti; Jose M Polo; Gustavo F Da Silva; Pedro Farinha; Rita Shaknovich; Randy D Gascoyne; Steven F Dowdy; Ari Melnick
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

Review 10.  Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas.

Authors:  Samir Parekh; Gilbert Privé; Ari Melnick
Journal:  Leuk Lymphoma       Date:  2008-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.